ABOUT US-AccurEdit Therapeutics

OVERVIEW

Going beyond disease management…

AccurEdit is committed to developing cures for diseases that are severe or life-threatening to patients worldwide.

About AccurEdit Therapeutics:

AccurEdit focuses on the development and commercialization of safe, effective and targeted in vivo gene editing and delivery technologies for hereditary and acquired diseases that are severe or life-threatening to patients worldwide.

AccurEdit has established an industry-leading end-to-end technology platform for in vivo gene editing therapy with focuses on RNA synthesis, editing, and delivery technologies.

In October 2023, AccurEdit became the first and only company in China to demonstrate safe and effective systemic CRISPR gene editing in humans.

AccurEdit follows a patient-oriented philosophy in product development. At AccurEdit we believe in a commercial model of sustainable growth through rapid development of single-dose curative therapy for applicable diseases via a highly efficient technology platform, rather than through patient's repeated or even lifelong medication.

MILESTONES

August 2023

August 2023

ART001, AccurEdit's first in vivo gene editing therapy for ATTR, initiated first-in-human IIT study. ART001 became the first LNP-based in vivo gene editing therapy to enter clinical stage in China.
March 2023

March 2023

AccurEdit has built China’s first (and one of very few in the world) industry-scale, end-to-end platform for in vivo gene editing that focuses on RNA synthesis, gene editing and delivery technologies. In March 2023, AccurEdit successfully completed the first lot of large scale manufacturing of ART001 using this platform.
January 2022

January 2022

Napoltec Life Sciences (Suzhou) Co., Ltd was formed jointly by AccurEdit and N1 Life, dedicated to co-developing next-generation delivery technologies based on biodegradable polymers to target non-liver organs.

N1 Life was co-founded by Dr. Xiaoyu Zang (Janice) and Prof. Paul A. Wender, Francis W. Bergstrom Professor of Chemistry & Chemical & System Biology at Stanford University and an elected member of the US National Academy of Sciences.
September 2021

September 2021

AccurEdit completed seed round financing.

The seed round was led by Legend Capital and Cormorant, both of which are influential in global pharmaceutical industry, especially in the US and China.
July 2021

July 2021

AccurEdit Therapeutics was founded.

LEADERSHIP

YONGZHONG WANG, Ph.D.

Founder, Chairman and CEO

YONGZHONG WANG, Ph.D.

Founder, Chairman and CEO

● Previously CEO of CMAB BioPharma, President of Pharmaceuticals and EVP of Simcere Pharmaceutical Group, CEO of Kanghong Biotech, and Staff Scientist of Genzyme Corporation.
● Led CMAB to become the fastest growing biopharmaceutical CDMO company in China, acquired by WuXi Biologics in early 2021.
● Managed a global team of more than 1,700 people and multiple commercialized companies at Simcere (publicly listed in HKEX).
● At Kanghong Biotech (publicly listed in China), first as the head of CMC and quality and later as the CEO, developed and marketed Conbercept, the first innovative biological drug with an INN to reach 1 billion RMB revenue in China and the first approved by the FDA to directly enter clinical phase III in 2016, which was rated as one of the top ten progresses in China's pharmaceutical industry.
● At Genzyme (was publicly listed in the US, later acquired by Sanofi), a key member of the team responsible for the post-market maintenance of the first and second cell therapies approved by the FDA and the development of key CMC projects for the first FDA-approved tissue engineering (cell+ matrix) product.
● Ph.D. from Tufts University, USA. Publications cited over 4,000 times by far.
JIALIN TAO, Ph.D.

Co-Founder, Head of Research

JIALIN TAO, Ph.D.

Co-Founder, Head of Research

● Extensive experience in global and Chinese pharmaceutical companies including Roche, CMC Biologics, Simcere Pharmaceutical Group, and CMAB BioPharma.
● At Roche, led the upstream development for Hemlibra, later served as the CMC lead for the entire project and helped Hemlibra gain approval as the first bi-specific antibody product in China at crucial meeting with CDE.
● At CMAB, led the development of all projects including monoclonal antibody, bi-specific antibody, ADC and fusion protein. Successfully established an industry-leading technology development platform and developed a number of patented technologies. Successfully gained IND clearance for 12 products in the US and China in two years, the most among all similar-sized CDMO companies during the same period.
● PhD from Case Western Reserve University, United States and bachelor from Tsinghua University.

HOME

ABOUT US

OVERVIEW

MILESTONES

LEADERSHIP

INVESTORS

SCIENCE & TECHNOLOGY PLATFORM

PIPELINE

PRESS RELEASE

CONTACT US